MedTrace Logo

A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes

NCT05371730 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-05-12

No results posted yet for this study

Summary

A clinical study to Evaluate the Safety and Efficacy of NK cells in the treatment of Myelodysplastic Syndromes

Conditions

  • Relapsed / Refractory Myelodysplastic Syndromes

Interventions

DRUG

NCR300

Intravenous infusion of NK cells（NCR300）

Sponsors & Collaborators

  • The First Affiliated Hospital of University of Science and Technology of China

    collaborator OTHER

  • Nuwacell Biotechnologies Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-30
Primary Completion
2025-05-30
Completion
2026-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05371730 on ClinicalTrials.gov